Compare Mesoblast Limited (MESO) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Quantumscape Corp — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Quantumscape Corp trades at $6.06 (market cap $3.62B). The key difference: Quantumscape Corp is the larger of the two by market cap, and Mesoblast Limited is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| MESO | QS | |
|---|---|---|
Market Cap | $2.17B | $3.62B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $18.44 |
52-Week Low | $12.88 | $5.86 |
Enterprise Value | $2.17B | $2.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
QuantumScape (QS) trades at $5.91, up 0.85% today, amid a bearish technical trend and negative profitability. The company reported a net loss of $435.05 million in 2025, with cash flow sustained by financing activities. Recent news highlights a joint research agreement with Honda, sparking investor interest in its solid-state battery technology.
The outlook remains speculative, hinging on successful commercialization of its battery technology. Key risks include persistent losses, high cash burn, and competitive pressures. Analyst sentiment is cautious, with no buy ratings and 72.7% hold recommendations, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
